SCHEMBL184399

SCHEMBL184399

CC(C)CNC(=O)c1cc(Cl)cc(C(=O)NCC(C)C)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.66
GAA P10253 1/20 0.66
KMT2A Q03164 1/20 0.66
HPGD P15428 3/20 0.63
KDM4E B2RXH2 2/20 0.58
GRN P28799 1/20 0.51
SORT1 Q99523 1/20 0.51
GPR139 Q6DWJ6 3/20 0.51
RAB9A P51151 2/20 0.50
LMNA P02545 2/20 0.50
ALDH1A1 P00352 2/20 0.50
ALOX12 P18054 2/20 0.50
NPC1 O15118 1/20 0.50
KCNH2 Q12809 1/20 0.50
MLYCD O95822 1/20 0.50
HTT P42858 2/20 0.49
NPSR1 Q6W5P4 1/20 0.49
TSHR P16473 1/20 0.48
FABP4 P15090 1/20 0.47
ALPL P05186 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2908793 0.90 HSD17B10 (0.78) HSD17B10GAAKMT2AHPGDKDM4E
SCHEMBL17847355 0.83 KMT2A (0.78) HSD17B10GAAKMT2AHPGDKDM4E
SCHEMBL14060468 0.80 HPGD (0.65) HSD17B10GAAKMT2AHPGDKDM4E
SCHEMBL1004027 0.79 GAA (0.62) HSD17B10GAAKMT2AHPGDKDM4E
SCHEMBL30358366 0.79 HPGD (0.48) HSD17B10GAAKMT2AHPGDKDM4E
SCHEMBL18748508 0.79 GAA (0.62) HSD17B10GAAKMT2AHPGDKDM4E
SCHEMBL10494518 0.79 SMN1; SMN2 (0.60) GAAKMT2AGRNSORT1GPR139
SCHEMBL17865783 0.78 MLYCD (0.73) HSD17B10GAAKMT2AHPGDKDM4E
SCHEMBL20206991 0.78 GAA (0.61) HSD17B10GAAKMT2AHPGDKDM4E
SCHEMBL4197802 0.77 HPGD (0.75) HSD17B10GAAKMT2AHPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501992-B2 Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-08-06 US disclosed
US-8501992-B2 Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-08-06 US disclosed
EP-2297103-B1 HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2012-01-04 EP disclosed
EP-2297103-B1 HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2012-01-04 EP disclosed
US-20110294793-A1 HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2011-12-01 US disclosed
US-20110294793-A1 HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2011-12-01 US disclosed
WO-2009152082-A1 HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294793-A1 HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BCL2, BAX, BCL2A1 HSD17B10 920/4885GAA 3464/4885KMT2A 2948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.